Martin Wilson Sells 1,175 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson sold 1,175 shares of Rocket Pharmaceuticals stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $13.05, for a total transaction of $15,333.75. Following the completion of the transaction, the general counsel now directly owns 63,560 shares of the company’s stock, valued at approximately $829,458. This represents a 1.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rocket Pharmaceuticals Trading Up 0.1 %

Shares of RCKT stock opened at $14.11 on Wednesday. Rocket Pharmaceuticals, Inc. has a 1 year low of $12.62 and a 1 year high of $32.53. The firm has a market capitalization of $1.29 billion, a PE ratio of -5.13 and a beta of 1.09. The stock has a fifty day moving average of $17.05 and a two-hundred day moving average of $19.76. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Novo Holdings A S raised its position in shares of Rocket Pharmaceuticals by 4.8% during the 2nd quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company’s stock worth $23,683,000 after buying an additional 50,000 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Rocket Pharmaceuticals during the second quarter worth approximately $2,144,000. First Turn Management LLC lifted its position in Rocket Pharmaceuticals by 10.8% in the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after purchasing an additional 60,317 shares during the period. Maverick Capital Ltd. boosted its stake in Rocket Pharmaceuticals by 1.0% during the 2nd quarter. Maverick Capital Ltd. now owns 3,928,312 shares of the biotechnology company’s stock valued at $84,577,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its position in shares of Rocket Pharmaceuticals by 3.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company’s stock valued at $83,001,000 after purchasing an additional 165,911 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Scotiabank assumed coverage on shares of Rocket Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price target for the company. Leerink Partners decreased their target price on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research note on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. increased their target price on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $51.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.